GLP-1s for Longevity: The Off-Label Science Behind Semaglutide, Rapamycin, Metformin, NR, and NMN

What Are GLP-1 Receptor Agonists and Why Do Longevity Clinicians Care?

GLP-1 receptor agonists were developed to lower blood glucose and body weight, but the SELECT cardiovascular outcomes trial showed they do substantially more. In SELECT (N=17,604), weekly semaglutide 2.4 mg cut major adverse cardiovascular events by 20% compared with placebo in adults with obesity but without diabetes over a mean follow-up of 34 months (P<0.001) [1]. That finding alone repositioned semaglutide from a metabolic drug to a potential cardiovascular longevity agent.

Beyond the heart, GLP-1 receptors are expressed in the brain, kidney, liver, and immune cells [2]. Activation of these receptors reduces systemic inflammation, lowers C-reactive protein, and may attenuate neuroinflammatory signaling pathways implicated in Alzheimer's disease [3]. The STEP-1 trial (N=1,961) documented 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [4], and excess adiposity is itself a driver of accelerated biological aging through chronic low-grade inflammation and insulin resistance.

Off-label prescribing of semaglutide (Ozempic, Wegovy) or liraglutide (Victoza, Saxenda) for healthspan in metabolically healthy adults with BMI <30 is legal in the United States but carries no FDA-approved indication for longevity [5]. Prescribers who do so are responsible for informed consent and ongoing safety monitoring.

Mechanistically, GLP-1 agonists appear to reduce mTORC1 signaling indirectly by improving insulin sensitivity and lowering circulating insulin, which is one of the primary mTOR activators [6]. This connects them to the same nutrient-sensing axis targeted by rapamycin and metformin.

Rapamycin (Sirolimus): The mTOR Inhibitor with the Longest Animal Track Record

Rapamycin is the most direct pharmacological intervention on the mTOR pathway available today. No other drug in this stack has as consistent a life-extension signal across model organisms. In the ITP (Interventions Testing Program) study coordinated by the National Institute on Aging, rapamycin fed to genetically heterogeneous mice starting at 20 months of age extended median lifespan by 9% in males and 14% in females [7]. That result was replicated across three independent sites, making it one of the most reproducible mammalian longevity findings on record.

mTORC1 (mechanistic target of rapamycin complex 1) integrates signals from amino acids, insulin, and growth factors to regulate protein synthesis, autophagy, and cellular senescence [8]. Chronic mTORC1 overactivation accelerates aging phenotypes; intermittent inhibition with rapamycin appears to restore autophagy and reduce senescent cell accumulation without the immunosuppression seen at the transplant doses (2-8 mg/day continuously) used in organ recipients [9].

Off-label longevity dosing in human protocols typically runs 1-6 mg once weekly, timed to allow trough levels to fall before the next dose. A 2023 paper in the journal Aging Cell by Mannick et al. tested a rapalog (RTB101) in older adults and found improvements in immune function at doses far below immunosuppressive thresholds [10]. No large prospective RCT has yet tested rapamycin specifically for human lifespan or healthspan as a primary endpoint.

Side effects at weekly low doses include mouth sores (aphthous ulcers) in roughly 10-15% of users, transient dyslipidemia (elevated triglycerides and LDL), and potential impairment of wound healing [11]. Baseline lipid panel, fasting glucose, and CBC are standard before starting. Women of childbearing age require contraception because sirolimus is teratogenic per the FDA label [5].

Combining rapamycin with semaglutide is theoretically additive: GLP-1 agonists lower insulin and thus reduce one upstream mTOR activator, while rapamycin blocks mTORC1 directly. No human RCT has tested this combination specifically for longevity endpoints.

Metformin Off-Label: The AMPK Activator with 60 Years of Safety Data

Metformin has been prescribed for type 2 diabetes since 1994 in the United States and since the 1950s in Europe [12]. Its longevity interest stems from three converging observations: it activates AMPK (AMP-activated protein kinase), it inhibits mitochondrial complex I, and retrospective data show diabetic patients on metformin outliving age-matched non-diabetic controls not on the drug.

That counterintuitive finding comes from a 2014 observational study by Bannister et al. published in Diabetes, Obesity and Metabolism (N=78,241 metformin users vs. 12,222 sulfonylurea users vs. 8,874 non-diabetic controls), which found that metformin users had lower all-cause mortality than both comparator groups over a median 2.8-year follow-up [13]. The authors were careful to note confounding limitations, but the signal was large enough to justify the prospective TAME (Targeting Aging with Metformin) trial, now enrolling 3,000 adults aged 65-79 with results expected around 2026 [14].

AMPK activation by metformin mimics a caloric-restriction signal. It phosphorylates and activates TSC2, which suppresses mTORC1, creating a partial overlap with rapamycin's mechanism [15]. AMPK also activates SIRT1, connecting metformin to the NAD+/sirtuin axis discussed below.

Off-label longevity dosing typically starts at 500 mg once daily with the evening meal, titrated to 500-1 to 000 mg twice daily based on GI tolerance. The most common side effects are GI (nausea, diarrhea) in up to 30% of users at initiation; extended-release formulations reduce this substantially [12]. Long-term use depletes vitamin B12 through reduced ileal absorption; annual B12 monitoring is standard per the American Diabetes Association guidelines [16].

One practical concern: metformin may blunt exercise-induced mitochondrial adaptations. A 2019 RCT by Walton et al. (N=53) published in Aging Cell found that metformin attenuated improvements in VO2max and mitochondrial respiration in older adults undergoing aerobic training compared to placebo [17]. Clinicians prescribing metformin to active longevity patients should time doses away from training sessions or consider drug holidays around structured training blocks.

Nicotinamide Riboside (NR): NAD+ Precursor with the Strongest Human Bioavailability Data

NAD+ (nicotinamide adenine dinucleotide) declines with age by approximately 50% between young adulthood and midlife based on tissue measurements in rodent models and indirect proxy measures in humans [18]. NAD+ is required for 400+ enzymatic reactions including those catalyzed by sirtuins (SIRT1-7) and PARPs (poly-ADP ribose polymerases), both implicated in DNA repair and epigenetic maintenance [19].

Nicotinamide riboside is an NAD+ precursor that bypasses rate-limiting steps in the classical NAD+ biosynthesis pathway. In a double-blind, placebo-controlled crossover trial (N=12) published in Nature Communications by Trammell et al., a single 1 to 000 mg oral dose of NR raised whole-blood NAD+ by an average of 2.7-fold [20]. A longer 6-week intervention in the Elysium Basis clinical study raised whole-blood NAD+ by 40% at 250 mg/day and by 90% at 500 mg/day, though these figures come from company-sponsored research and require independent replication [21].

At the cellular level, raising NAD+ activates SIRT1, which deacetylates PGC-1alpha to stimulate mitochondrial biogenesis, and activates SIRT3, which protects mitochondrial function [22]. These effects are consistent with the broader longevity hypothesis that declining mitochondrial quality drives aging phenotypes.

Human trial results on functional outcomes are more modest. A 12-week RCT by Martens et al. (N=30 healthy middle-aged and older adults) published in Nature Aging found that 1 to 000 mg/day of NR significantly raised NAD+ metabolites but did not significantly improve blood pressure, arterial stiffness, or mitochondrial function in skeletal muscle compared to placebo [23]. Raising the molecule does not automatically translate to clinical benefit, a distinction patients frequently miss.

NR is sold as a dietary supplement in the United States and is not FDA-regulated as a drug. Common doses in clinical studies range from 250 mg to 1 to 000 mg/day; GI side effects are rare at these doses [24].

Nicotinamide Mononucleotide (NMN): Similar Target, Different Entry Point

NMN is another NAD+ precursor that enters the biosynthesis pathway one step closer to NAD+ than NR does. In a randomized, placebo-controlled, double-blind trial (N=25 postmenopausal women with prediabetes) by Yoshino et al. published in Science by Washington University researchers, 250 mg/day of NMN for 10 weeks significantly improved muscle insulin sensitivity and increased expression of genes involved in muscle remodeling compared to placebo [25]. This is the most rigorous human evidence for NMN to date.

A separate 12-week Japanese RCT (N=10 healthy men) published in Endocrine Journal by Irie et al. found that oral NMN 100-500 mg/day was safe and well-tolerated with no serious adverse events and modestly raised blood NAD+ metabolites [26].

NMN differs from NR in its transport mechanism. NMN may use the Slc12a8 transporter for direct intestinal uptake rather than requiring extracellular conversion to NR first, though this is still debated in the literature [27]. From a practical standpoint, both NR and NMN raise NAD+ in humans; no head-to-head RCT has established clinical superiority of one over the other.

NMN's regulatory status shifted in 2022 when the FDA determined that NMN is excluded from the dietary supplement definition because it was first investigated as a new drug before being marketed as a supplement [28]. This ruling did not withdraw NMN products from sale but created legal ambiguity around commercial availability in the United States.

How These Five Agents Converge on the Same Aging Pathways

All five agents in this stack act on three interconnected nutrient-sensing networks: mTOR, AMPK, and NAD+/SIRT1. The table below maps each agent to its primary target and downstream effect.

GLP-1 agonists (semaglutide, liraglutide): Reduce circulating insulin and suppress upstream mTOR activators. Also reduce systemic inflammation via GLP-1R signaling in immune cells [2]. Secondary AMPK activation through improved insulin sensitivity [6].

Rapamycin (sirolimus): Allosteric inhibitor of mTORC1. Directly restores autophagy and reduces senescent cell burden. Animal data strongest; human longevity RCT data absent [7].

Metformin: Primary AMPK activator via mitochondrial complex I inhibition. Downstream mTOR suppression. Weak NAD+/SIRT1 activation through AMPK-SIRT1 crosstalk [15].

NR: NAD+ precursor. Raises intracellular NAD+ to activate SIRT1, SIRT3, and PARP-1. Downstream mitochondrial biogenesis via PGC-1alpha [22].

NMN: NAD+ precursor with a distinct transporter. Same downstream targets as NR. Human insulin-sensitivity data from Yoshino et al. are the most clinically actionable [25].

The American Federation for Aging Research, which oversees the TAME trial, has characterized this convergence plainly: "Aging itself is a modifiable risk factor, and interventions that target fundamental biological aging processes have the potential to prevent or delay multiple chronic diseases simultaneously" [14].

Stacking all five simultaneously is not standard practice and introduces interaction risks. Rapamycin combined with metformin produces additive mTOR suppression but may worsen dyslipidemia [9]. NR or NMN combined with semaglutide has no published safety data. Most longevity clinicians sequence additions one at a time with 8-12 weeks of baseline labs between introductions.

Who Is a Candidate for an Off-Label Longevity Protocol?

Candidacy depends on the agent. Semaglutide off-label for metabolically healthy adults typically requires BMI <30 with documented metabolic risk factors such as elevated fasting insulin, impaired glucose tolerance, or a family history of cardiovascular disease. The SELECT trial enrolled adults with BMI 27 or above, which defines the evidence boundary [1].

Metformin off-label is most defensible in adults with prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%), a population in which it reduces progression to type 2 diabetes by 31% over 2.8 years per the Diabetes Prevention Program (N=3,234) [29]. Prescribing to normoglycemic adults with no metabolic risk is harder to justify with current evidence.

Rapamycin off-label candidacy is the least well-defined. Most protocols require age 45 or above, absence of active infection, no immunocompromised state, and no concurrent calcineurin inhibitor use [11]. Baseline and quarterly lipid panels plus fasting glucose are standard.

NR and NMN are supplements, not prescription drugs, so formal prescribing criteria do not apply. Adults concerned about age-related NAD+ decline are the typical buyers. The evidence does not currently support either supplement as a replacement for exercise, sleep, or caloric moderation in improving metabolic health.

A board-certified endocrinologist or longevity medicine specialist should be involved whenever GLP-1 agonists, rapamycin, or metformin are prescribed for off-label purposes. The American Association of Clinical Endocrinology recommends comprehensive metabolic and cardiovascular risk assessment before initiating any anti-obesity or metabolic-modifying pharmacotherapy [30].

Monitoring, Safety, and Drug Interactions

Semaglutide: Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. GI side effects (nausea, vomiting) affect 20-44% of patients during dose escalation per the STEP program [4]. Pancreatitis is rare but requires discontinuation if suspected.

Rapamycin (sirolimus): Monitor lipids, fasting glucose, and CBC every 3 months during the first year. Avoid grapefruit (CYP3A4 inhibition raises sirolimus blood levels substantially). Wound healing may be impaired; hold 2 weeks before elective surgery [11].

Metformin: Contraindicate in eGFR <30 mL/min/1.73m2 due to lactic acidosis risk. Hold 48 hours before iodinated contrast procedures. Annual B12 level; supplement if below 300 pg/mL [16].

NR: Generally well tolerated. Doses above 3 to 000 mg/day have shown nausea and flushing in some participants [24]. No major drug interactions established in current literature.

NMN: FDA regulatory status is uncertain in the United States [28]. GI tolerance is generally good at 250-500 mg/day. Avoid in active malignancy until more safety data exist, given the theoretical concern about NAD+-dependent cancer cell metabolism [19].

The SELECT trial protocol required baseline and annual assessments of HbA1c, lipids, renal function, and thyroid markers in all semaglutide participants [1]. That monitoring template is a reasonable minimum standard for any multi-agent longevity protocol.